N-Acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6/1 mouse model of Huntington's disease

Translational Psychiatry

Volumn 5, Issue 1, 2015, Pages

  Wright, D J ^a,b   Renoir, T ^a   Smith, Z M ^b   Frazier, A E ^a,c   Francis, P S ^b   Thorburn, D R ^a,c   McGee, S L ^b,d   Hannan, A J ^a   Gray, L J ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b DEAKIN UNIVERSITY   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

^d BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; BIOLOGICAL MARKER; GLUTAMIC ACID; HUNTINGTIN; POLYGLUTAMINE; SODIUM GLUCOSE COTRANSPORTER 1; EXCITATORY AMINO ACID TRANSPORTER 2; SCAVENGER; SLC1A2 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN CORTEX; CAG REPEAT; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFICACY; EXCITOTOXICITY; FEMALE; HUNTINGTON CHOREA; MALE; MITOCHONDRION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PSYCHOMOTOR DISORDER; ANIMAL; ANIMAL BEHAVIOR; BRAIN; DISEASE COURSE; DISEASE MODEL; DRUG EFFECTS; GAIT; METABOLISM; MOTOR ACTIVITY; ORGAN SIZE; PATHOLOGY; TRANSGENIC MOUSE;

ACETYLCYSTEINE; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; EXCITATORY AMINO ACID TRANSPORTER 2; FREE RADICAL SCAVENGERS; GAIT; HUNTINGTON DISEASE; MICE; MICE, TRANSGENIC; MITOCHONDRIA; MOTOR ACTIVITY; ORGAN SIZE; OXIDATIVE STRESS;

EID: 84925277696     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2014.131     Document Type: Article

References (68)

1. MacDonald ME, Ambrose CM, Duyao MP, Myers RH, Lin C, Srinidhi L et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72: 971-983
2. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985; 44: 559-577
3. Ferrante RJ, Kowall NW, Beal MF, Richardson EP Jr, Bird ED, Martin JB. Selective sparing of a class of striatal neurons in Huntington's disease. Science 1985; 230: 561-563
4. Graveland GA, Williams RS, DiFiglia M. Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science 1985; 227: 770-773
5. Browne SE, Ferrante RJ, Beal MF. Oxidative stress in Huntington's disease. Brain Pathol 1999; 9: 147-163
6. Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MM et al. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol 1997; 41: 646-653
7. Tabrizi SJ, Cleeter MW, Xuereb J, Taanman JW, Cooper JM, Schapira AH. Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann Neurol 1999; 45: 25-32
8. Estrada Sanchez AM, Mejia-Toiber J, Massieu L. Excitotoxic neuronal death and the pathogenesis of Huntington's disease. Arch Med Res 2008; 39: 265-276
9. Dean O, Giorlando F, Berk M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci 2011; 36: 78-86
10. Klepac N, Relja M, Klepac R, Hecimovic S, Babic T, Trkulja V. Oxidative stress parameters in plasma of Huntington's disease patients, asymptomatic Huntington's disease gene carriers and healthy subjects: A cross-sectional study. J Neurol 2007; 254: 1676-1683
11. Bogdanov MB, Andreassen OA, Dedeoglu A, Ferrante RJ, Beal MF. Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease. J Neurochem 2001; 79: 1246-1249
12. Aruoma OI, Halliwell B, Hoey BM, Butler J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med 1989; 6: 593-597
13. Atkuri KR, Mantovani JJ, Herzenberg LA, Herzenberg LA. N-Acetylcysteine-a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol 2007; 7: 355-359
14. Paul BD, Sbodio JI, Xu R, Vandiver MS, Cha JY, Snowman AM et al. Cystathionine [ggr]-lyase deficiency mediates neurodegeneration in Huntington's disease. Nature 2014; 509: 96-100
15. Portera-Cailliau C, Hedreen JC, Price DL, Koliatsos VE. Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models. J Neurosci 1995; 15: 3775-3787
16. Cepeda C, Hurst RS, Calvert CR, Hernandez-Echeagaray E, Nguyen OK, Jocoy E et al. Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J Neurosci 2003; 23: 961-969
17. Lucetti C, Gambaccini G, Bernardini S, Dell'Agnello G, Petrozzi L, Rossi G et al. Amantadine in Huntington's disease: open-label video-blinded study. Neurol Sci 2002; 23: S83-S84
18. Beister A, Kraus P, Kuhn W, Dose M, Weindl A, Gerlach M. The N-methyl-Daspartate antagonist memantine retards progression of Huntington's disease. In: Müller T, Riederer P (eds). Focus on Extrapyramidal Dysfunction, vol. 68. Springer: Vienna, 2004, pp 117-22
19. Lievens JC, Woodman B, Mahal A, Spasic-Boscovic O, Samuel D, Kerkerian-Le Goff L et al. Impaired glutamate uptake in the R6 Huntington's disease transgenic mice. Neurobiol Dis 2001; 8: 807-821
20. Behrens PF, Franz P, Woodman B, Lindenberg KS, Landwehrmeyer GB. Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. Brain 2002; 125: 1908-1922
21. Sari Y, Prieto AL, Barton SJ, Miller BR, Rebec GV. Ceftriaxone-induced up-regulation of cortical and striatal GLT1 in the R6/2 model of Huntington's disease. J Biomed Sci 2010; 17: 62
22. McBean GJ. Cerebral cystine uptake: A tale of two transporters. Trends Pharmacol Sci 2002; 23: 299-302
23. Sanacora G, Banasr M. From pathophysiology to novel antidepressant drugs: glial contributions to the pathology and treatment of mood disorders. Biol Psychiatry 2013; 73: 1172-1179
24. McBean GJ, Flynn J. Molecular mechanisms of cystine transport. Biochem Soc Trans 2001; 29: 717-722
25. Bender AS, Reichelt W, Norenberg MD. Characterization of cystine uptake in cultured astrocytes. Neurochem Int 2000; 37: 269-276
26. Moussawi K, Pacchioni A, Moran M, Olive MF, Gass JT, Lavin A et al. N-Acetylcysteine reverses cocaine-induced metaplasticity. Nat Neurosci 2009; 12: 182-189
27. Kupchik YM, Moussawi K, Tang X-C, Wang X, Kalivas BC, Kolokithas R et al. The effect of N-acetylcysteine in the nucleus accumbens on neurotransmission and relapse to cocaine. Biol Psychiatry 2012; 71: 978-986
28. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996; 87: 493-506
29. van Dellen A, Cordery PM, Spires TL, Blakemore C, Hannan AJ. Wheel running from a juvenile age delays onset of specific motor deficits but does not alter protein aggregate density in a mouse model of Huntington's disease. BMC Neurosci 2008; 9: 34
30. Miller BR, Dorner JL, Shou M, Sari Y, Barton SJ, Sengelaub DR et al. Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse. Neuroscience 2008; 153: 329-337
31. Petr GT, Schultheis LA, Hussey KC, Sun Y, Dubinsky JM, Aoki C et al. Decreased expression of GLT-1 in the R6/2 model of Huntington's disease does not worsen disease progression. Eur J Neurosci 2013; 38: 2477-2490
32. Renoir T, Zajac MS, Du X, Pang T, Leang L, Chevarin C et al. Sexually dimorphic serotonergic dysfunction in a mouse model of Huntington's disease and depression. PLoS One 2011; 6: e22133
33. Smith ZM, Terry JM, Barnett NW, Gray LJ, Wright DJ, Francis PS. Enhancing permanganate chemiluminescence detection for the determination of glutathione and glutathione disulfide in biological matrices. Analyst 2014; 139: 2416-2422
34. Rogers GW, Brand MD, Petrosyan S, Ashok D, Elorza AA, Ferrick DA et al. High throughput microplate respiratory measurements using minimal quantities of isolated mitochondria. PLoS One 2011; 6: e21746
35. McGee SL, Sadli N, Morrison S, Swinton C, Suphioglu C. DHA protects against zinc mediated alterations in neuronal cellular bioenergetics. Cell Physiol Biochem 2011; 28: 157-162
36. Bannai S, Christensen HN, Vadgama JV, Ellory JC, Englesberg E, Guidotti GG et al. Amino acid transport systems. Nature 1984; 311: 308
37. Dalle-Donne I, Rossi R, Giustarini D, Milzani A, Colombo R. Protein carbonyl groups as biomarkers of oxidative stress. Clin Chim Acta 2003; 329: 23-38
38. Slaughter JR, Martens MP, Slaughter KA. Depression and Huntington's disease: prevalence, clinical manifestations, etiology, and treatment. CNS Spectr 2001; 6: 306-326
39. Carter RJ, Lione LA, Humby T, Mangiarini L, Mahal A, Bates GP et al. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci 1999; 19: 3248-3257
40. Underwood BR, Imarisio S, Fleming A, Rose C, Krishna G, Heard P et al. Antioxidants can inhibit basal autophagy and enhance neurodegeneration in models of polyglutamine disease. Hum Mol Genet 2010; 19: 3413-3429
41. Ma YT, Galluzzi L, Zitvogel L, Kroemer G. Autophagy and cellular immune responses. Immunity 2013; 39: 211-227
42. Mo C, Pang TY, Ransome MI, Hill RA, Renoir T, Hannan AJ. High stress hormone levels accelerate the onset of memory deficits in male Huntington's disease mice. Neurobiol Dis 2014; 69: 248-262
43. Maheshwari M, Bhutani S, Das A, Mukherjee R, Sharma A, Kino Y et al. Dexamethasone induces heat shock response and slows down disease progression in mouse and fly models of Huntingtons disease. Hum Mol Genet 2014; 23: 2737-2751
44. Pallier PN, Drew CJG, Morton AJ. The detection and measurement of locomotor deficits in a transgenic mouse model of Huntington's disease are task-and protocol-dependent: influence of non-motor factors on locomotor function. Brain Res Bull 2009; 78: 347-355
45. Du X, Pang TYC, Hannan AJ. A tale of two maladies? Pathogenesis of depression with and without the Huntington's disease gene mutation. Front Neurol 2013; 4: 81
46. Overstreet DH. Modeling depression in animal models. Methods Mol Biol 2012; 829: 125-144
47. Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I et al. N-acetyl cysteine for depressive symptoms in bipolar disorder-a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008; 64: 468-475
48. Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM, Schapira AH. Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol 1996; 39: 385-389
49. Grunewald T, Beal MF. Bioenergetics in Huntington's disease. Ann N Y Acad Sci 1999; 893: 203-213
50. Tabrizi SJ, Workman J, Hart PE, Mangiarini L, Mahal A, Bates G et al. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann Neurol 2000; 47: 80-86
51. Faideau M, Kim J, Cormier K, Gilmore R, Welch M, Auregan G et al. In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: A correlation with Huntington's disease subjects. Hum Mol Genet 2010; 19: 3053-3067
52. Estrada-Sanchez AM, Montiel T, Segovia J, Massieu L. Glutamate toxicity in the striatum of the R6/2 Huntington's disease transgenic mice is age-dependent and correlates with decreased levels of glutamate transporters. Neurobiol Dis 2009; 34: 78-86
53. Lewerenz J, Hewett SJ, Huang Y, Lambros M, Gout PW, Kalivas PW et al. The cystine/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities. Antioxid Redox Signal 2013; 18: 522-555
54. Knackstedt LA, LaRowe S, Mardikian P, Malcolm R, Upadhyaya H, Hedden S et al. The role of cystine-glutamate exchange in nicotine dependence in rats and humans. Biol Psychiatry 2009; 65: 841-845
55. Dringen R, Hirrlinger J. Glutathione pathways in the brain. Biol Chem 2003; 384: 505-516
56. Berk M, Malhi GS, Gray LJ, Dean OM. The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol Sci 2013; 34: 167-177
57. Garcia O, Almeida A, Massieu L, Bolanos JP. Increased mitochondrial respiration maintains the mitochondrial membrane potential and promotes survival of cerebellar neurons in an endogenous model of glutamate receptor activation. J Neurochem 2005; 92: 183-190
58. Wadey AL, Muyderman H, Kwek PT, Sims NR. Mitochondrial glutathione uptake: characterization in isolated brain mitochondria and astrocytes in culture. J Neurochem 2009; 109: 101-108
59. Perry TL, Hansen S, Gandham SS. Postmortem changes of amino compounds in human and rat brain. J Neurochem 1981; 36: 406-410
60. Siddiqui A, Rivera-Sanchez S, Castro MDR, Acevedo-Torres K, Rane A, Torres-Ramos CA et al. Mitochondrial DNA damage is associated with reduced mitochondrial bioenergetics in Huntington's disease. Free Radic Biol Med 2012; 53: 1478-1488
61. Turrens JF. Mitochondrial formation of reactive oxygen species. J Physiol 2003; 552: 335-344
62. Brennan WA Jr., Bird ED, Aprille JR. Regional mitochondrial respiratory activity in Huntington's disease brain. J Neurochem 1985; 44: 1948-1950
63. Benchoua A, Trioulier Y, Zala D, Gaillard M-C, Lefort N, Dufour N et al. Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin. Mol Biol Cell 2006; 17: 1652-1663
64. Butterworth J, Yates CM, Reynolds GP. Distribution of phosphate-activated glutaminase, succinic dehydrogenase, pyruvate dehydrogenase andgammaglutamyl transpeptidase in post-mortem brain from Huntington's disease and agonal cases. J Neurol Sci 1985; 67: 161-171
65. Zhang SF, Hennessey T, Yang L, Starkova NN, Beal MF, Starkov AA. Impaired brain creatine kinase activity in Huntington's disease. Neurodegener Dis 2011; 8: 194-201
66. Mochel F, Durant B, Meng X, O'Callaghan J, Yu H, Brouillet E et al. Early alterations of brain cellular energy homeostasis in Huntington disease models. J Biol Chem 2012; 287: 1361-1370
67. Drose S, Brandt U. Molecular mechanisms of superoxide production by the mitochondrial respiratory chain. Adv Exp Med Biol 2012; 748: 145-169
68. Dean OM, Bush AI, Berk M. Translating the Rosetta Stone of N-acetylcysteine. Biol Psychiatry 2012; 71: 935-936.